IBTROZI™ (Taletrectinib), FDA-Approved Treatment, Available at Biologics by McKesson
Cary, N.C. , June 11, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
Improving Oncology Patient Outcomes: The Future of Risk-Based Care
Research shows that Biologics by McKesson’s pioneering risk-based care program maximizes patients’ time on therapy, leading to better oncology patient outcomes.